文献速递垂体与肾上腺疾病肥胖与代谢综合征

Luscan-Lumish 综合征一例:生长激素信号增强的可能参与

A Case of Luscan-Lumish Syndrome: Possible Involvement of Enhanced GH Signaling.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

本文报告一例20岁男性Luscan-Lumish综合征(LLS)患者,表现为高身材、肥胖、Chiari I畸形及肢端肥大样特征,无癫痫或智力障碍。全外显子测序发现SETD2基因新发杂合突变(c.236T>A, p.L79H)。患者皮肤成纤维细胞生长更快,且GH诱导的STAT5b磷酸化与转录活性增强、IGF-1表达增加,提示GH信号增强可能参与LLS发病。

要点

  • 对无垂体瘤的巨人症患者,需将LLS纳入鉴别诊断。
  • SETD2基因突变可导致LLS,本例为新发突变c.236T>A(p.L79H)。
  • LLS患者细胞中GH诱导的STAT5b信号增强,提示GH信号通路参与。

核心结论

  • 本例为携带SETD2新发突变的轻度LLS,无神经系统症状。
  • LLS应在无垂体瘤的巨人症患者中鉴别。
  • 首次提示异常GH信号可能参与LLS发生。

研究设计与样本

  • 病例报告:一名20岁男性因高身材就诊。
  • 进行了临床评估、垂体MRI、全外显子测序及皮肤成纤维细胞功能实验。

主要发现

  • 身高188.2 cm(+3.18 SD),BMI 28.4 kg/m2,有肢端过度生长、下颌错颌及突颌。
  • 血清GH、IGF-1及75g口服葡萄糖后GH谷值均在正常范围。
  • 垂体MRI无垂体腺瘤,但显示Chiari I畸形。
  • 全外显子测序发现SETD2新发杂合胚系突变(c.236T>A, p.L79H)。
  • 患者皮肤成纤维细胞生长快于父亲及对照,且GH诱导的STAT5b酪氨酸磷酸化与转录活性增强、IGF-1表达增加。

临床怎么用

  • 对高身材且无垂体瘤的患者,应考虑LLS并进行SETD2基因检测。
  • 即使GH/IGF-1水平正常,也需警惕组织水平GH信号增强的可能。

局限性

  • 仅为单例病例报告,机制推断需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Luscan-Lumish syndrome (LLS) is characterized by postnatal overgrowth, obesity, Chiari I malformation, seizures, and intellectual disability. SET domain-containing protein 2 (SETD2) is a histone methyltransferase, where mutations in the gene are associated with the development of LLS. However, mechanisms underlying LLS remain unclear. CASE DESCRIPTION: A 20-year-old man was referred to our hospital because of tall stature. His body height was 188.2 cm (+3.18 SD) and he showed obesity with a body mass index of 28.4 kg/m2. He exhibited acral overgrowth, jaw malocclusion, and prognathism, but no history of seizures, intellectual disability, or speech delay. Serum growth hormone (GH), insulin-like growth factor 1 (IGF-1), and nadir GH levels after administration of 75 g oral glucose were within normal range. Pituitary magnetic resonance imaging showed no pituitary adenoma, but Chiari I malformation. Whole exome sequencing analysis of the proband revealed a de novo heterozygous germline mutation in SETD2 (c.236T>A, p.L79H). Skin fibroblasts derived from the patient grew faster than those from his father and the control subject. In addition, these cells showed enhanced tyrosine phosphorylation and transcriptional activity of signal transducer and activator of transcription 5b (STAT5b) and increased IGF-1 expression induced by GH. CONCLUSION: This is a mild case of LLS with a novel mutation in SETD2 without neurological symptoms. LLS should be differentiated in a patient with gigantism without pituitary tumors. Although further investigation is necessary, this is the first study to suggest the involvement of aberrant GH signaling in the development of LLS.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Suda K, Fukuoka H, Iguchi G, et al. A Case of Luscan-Lumish Syndrome: Possible Involvement of Enhanced GH Signaling. J Clin Endocrinol Metab. 2021. PMID: 33248444. doi:10.1210/clinem/dgaa893

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。